Patents by Inventor Yu-Hwa Huang

Yu-Hwa Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized and Affinity-Matured Anti-CEACAM1 Antibodies
    Publication number: 20220025040
    Abstract: Provided herein are recombinant antibodies and antigen-binding fragments thereof useful for binding to and inhibiting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). Also provided are methods of using the disclosed CEACAM1 antibodies and antigen-binding fragments thereof for reducing T-cell tolerance and for the treatment of cancer.
    Type: Application
    Filed: December 9, 2019
    Publication date: January 27, 2022
    Inventors: Richard S. Blumberg, Yu-Hwa Huang, Amit Gandhi, Monica Bertagnolli, Charles Yoon, Robert George Edward Holgate, Arron Robert Hearn, Susan Dana Jones
  • MODULATION OF THE IMMUNE RESPONSE
    Publication number: 20200095284
    Abstract: Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.
    Type: Application
    Filed: November 6, 2019
    Publication date: March 26, 2020
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: RICHARD S. BLUMBERG, VIJAY K. KUCHROO, YU-HWA HUANG, CHEN ZHU, ANA C. ANDERSON
  • Modulation of the immune response
    Patent number: 10513540
    Abstract: Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: December 24, 2019
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Richard S. Blumberg, Vijay K. Kuchroo, Yu-Hwa Huang, Chen Zhu, Ana C. Anderson
  • ENHANCEMENT OF THE IMMUNE RESPONSE
    Publication number: 20190201524
    Abstract: The technology described herein relates to compositions and methods for enhancing the immune response and/or reducing T cell tolerance in a subject. In some embodiments, the technology described herein relates to administering inhibitors of two or more of CEACAM1, PD1, and/or LAP to, e.g., synergistically reduce T cell tolerance.
    Type: Application
    Filed: October 19, 2018
    Publication date: July 4, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Yu-Hwa HUANG
  • INTERACTIONS BETWEEN CEACAM AND TIM FAMILY MEMBERS
    Publication number: 20180298095
    Abstract: Described herein are compositions and methods for modulating immune response, which can be upregulated or down regulated by enhancement or inhibition of interactions between CEACAM family members and TIM family members.
    Type: Application
    Filed: April 24, 2015
    Publication date: October 18, 2018
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Yu-Hwa HUANG, Yasuyuki KONDO, Amit GANDHI
  • INTERACTIONS BETWEEN CEACAM AND TIM FAMILY MEMBERS
    Publication number: 20180153986
    Abstract: Described herein are compositions and methods for modulating immune response, which can be upregulated or down regulated by enhancement or inhibition of interactions between CEACAM family members and TIM family members.
    Type: Application
    Filed: April 24, 2015
    Publication date: June 7, 2018
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Yu-Hwa HUANG, Yasuyuki KONDO, Amit GANDHI
  • ANTI-CEACAM1 RECOMBINANT ANTIBODIES FOR CANCER THERAPY
    Publication number: 20170327578
    Abstract: Provided herein are recombinant monoclonal antibodies and antigen-binding portions thereof useful in inhibiting CEACAM1 in tumor cells, and methods of their use in anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, particularly pancreatic cancer.
    Type: Application
    Filed: December 20, 2016
    Publication date: November 16, 2017
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Yu-Hwa HUANG, Nalan UTKU
  • Anti-CEACAM1 recombinant antibodies for cancer therapy
    Patent number: 9556271
    Abstract: Provided herein are recombinant monoclonal antibodies and antigen-binding portions thereof useful in inhibiting CEACAM1 in tumor cells, and methods of their use in anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, particularly pancreatic cancer.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: January 31, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Richard S. Blumberg, Yu-Hwa Huang, Nalan Utku
  • ENHANCEMENT OF THE IMMUNE RESPONSE
    Publication number: 20150273056
    Abstract: The technology described herein relates to compositions and methods for enhancing the immune response and/or reducing T cell tolerance in a subject. In some embodiments, the technology described herein relates to administering inhibitors of two or more of CEACAM1, PD1, and/or LAP to, e.g., synergistically reduce T cell tolerance.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 1, 2015
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S Blumberg, Yu-Hwa Huang
  • MODULATION OF THE IMMUNE RESPONSE
    Publication number: 20150225457
    Abstract: Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.
    Type: Application
    Filed: July 30, 2013
    Publication date: August 13, 2015
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. Blumberg, Vijay K. Kuchroo, Yu-Hwa Huang, Chen Zhu, Ana C. Anderson
  • ANTI-CEACAM1 RECOMBINANT ANTIBODIES FOR CANCER THERAPY
    Publication number: 20140328841
    Abstract: Provided herein are recombinant monoclonal antibodies and antigen-binding portions thereof useful in inhibiting CEACAM1 in tumor cells, and methods of their use in anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, particularly pancreatic cancer.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 6, 2014
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. Blumberg, Yu-Hwa Huang, Nalan Utku